Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratracheal budesonide plus surfactant vs surfactant alone to prevent bronchopulmonary dysplasia in preterm infants
IRCT20221016056205N1Phase 3Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of budesonide in bronchopulmonary dysplasia (BPD) and respiratory distress syndrome (RDS) (2 arms), sponsored by Alborz University of Medical Sciences. Primary endpoint: Prevention of bronchopulmonary dysplasia. Started Nov 2022; status: completed.
02
Drugs
budesonide
03
Conditions
bronchopulmonary dysplasia (BPD)respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on IRCT20221016056205N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221016056205N1.